Skip to content

Clinical study on the treatment of damp heat internal syndrome in children with abdominal type Henoch Scholein Purpura using the formula of clearing heat removing dampness and activating blood circulation

Clinical study on the treatment of damp heat internal syndrome in children with abdominal type Henoch Scholein Purpura using the formula of clearing heat removing dampness and activating blood circulation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000509
Enrollment
Unknown
Registered
2024-10-01
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Henoch Scholein Purpura

Interventions

Control group:Oral Chinese herbal Methylprednisolone should be administered intravenously at a dose of 1-2mg/kg once every 12 hours, and gradually reduced after symptom control.medicine
Observation group:On the basis of the control group oral administration of Qingre Lishi Huoxue Formula was added.

Sponsors

Beijing Children's Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
3 Years to 16 Years

Inclusion criteria

Inclusion criteria: 16 years old and = 3 years old. (4) The patient is a hospitalized patient. (5) The subjects and their legal guardians fully understand the research content and sign informed consent. (1) Complies with the clinical diagnosis of abdominal HSP. (2) Those who meet the traditional Chinese medicine syndrome diagnosis of damp heat accumulation syndrome. (3) Age = 16 years old and = 3 years old. (4) The patient is a hospitalized patient. (5) The subjects and their legal guardians fully understand the research content and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Those who experience severe vomiting or gastrointestinal bleeding and are not suitable for oral Chinese medicine treatment. (2) HSP nephritis and those who have had abnormal urine tests before enrollment including microscopic hematuria proteinuria and blood Urine proteinuria or tubular urine. (3) Serious primary diseases of the heart liver kidneys and hematopoietic system as well as psychiatric patients and those with moderate to severe illnesses Symptoms of the central nervous system such as coma subarachnoid hemorrhage optic neuritis and Guillain Barr é syndrome are rare Symptoms seen. (4) According to the researchers' judgment there are other patients who may reduce the likelihood of inclusion or complicate the inclusion process. (5) Participants in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Relief time for gastrointestinal symptoms;

Secondary

MeasureTime frame
Changes in Traditional Chinese Medicine symptom scores;Time for skin purpura to subside;The recurrence rate within 4 weeks after the start of follow-up treatment;Thickening of intestinal wall by gastrointestinal ultrasound;

Countries

China

Contacts

Public ContactLiuchang

Beijing Children's Hospital Affiliated to Capital Medical University

liuchan3704@sina.com13520881081

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026